FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994489315> ?p ?o ?g. }

• W2994489315 abstract "A strong correlation between raised aldosterone levels and increased risk of thrombotic disorders has been provided. Clinical studies have demonstrated the benefits of the addition of the aldosterone receptor antagonist to the standard therapy with angiotensin-converting enzyme inhibitor in the reduction of cardiovascular events in patients. We suggest that the benefits of this dual renin-angiotensin-aldosterone system (RAAS) blockade may be related to the drug's effects on the hemostatic and oxidative balance. Thus, we investigated the effect of combined spironolactone (SPIRO) and quinapril (QUIN) administration on thrombosis, hemostasis and oxidative stress in hypertensive rats. A two-kidney, one-clip model of renovascular hypertension in Wistar rats was used. QUIN, SPIRO, or QUIN + SPIRO were administered for 10 days. Venous thrombosis was induced by vena cava ligation. Thrombus weight and incidences of thrombosis were assessed. Bleeding time, platelet adhesion, tissue factor (TF), tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), thrombin activatable fibrynolysis inhibitor (TAFI), malonyl dialdehyde, and hydrogen peroxide plasma levels were assayed. Aortic expression of NADPH oxidase and superoxidase dismutase were measured. We observed significant RAAS activation associated with hypercoagulability and oxidative stress augmentation in renovascular hypertensive rats. Thrombosis was reduced only in rats treated with QUIN + SPIRO. In all groups, decreases in TF, PAI-1, and TAFI levels were observed, however in the QUIN + SPIRO group those changes were more pronounced. The inhibition of platelet adhesion was also stronger in rats treated with QUIN + SPIRO. The oxidative stress parameters were markedly reduced in rats treated with QUIN or SPIRO, although the most evident changes were observed in the QUIN + SPIRO group. Dual RAAS blockade with aldosterone receptor antagonist and angiotensin-converting enzyme inhibitor provides additional benefits for experimental thrombosis associated with the antiplatelet, anticoagulative, profibrinolytic, and antioxidative effects in renovascular hypertensive rats." @default.
• W2994489315 created "2019-12-13" @default.
• W2994489315 creator A5007053672 @default.
• W2994489315 creator A5045560136 @default.
• W2994489315 creator A5049667988 @default.
• W2994489315 creator A5053086036 @default.
• W2994489315 creator A5057776837 @default.
• W2994489315 creator A5061906116 @default.
• W2994489315 creator A5063736852 @default.
• W2994489315 date "2018-04-01" @default.
• W2994489315 modified "2023-09-28" @default.
• W2994489315 title "Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats." @default.
• W2994489315 doi "https://doi.org/10.26402/jpp.2018.2.10" @default.
• W2994489315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29980144" @default.
• W2994489315 hasPublicationYear "2018" @default.
• W2994489315 type Work @default.
• W2994489315 sameAs 2994489315 @default.
• W2994489315 citedByCount "1" @default.
• W2994489315 countsByYear W29944893152020 @default.
• W2994489315 crossrefType "journal-article" @default.
• W2994489315 hasAuthorship W2994489315A5007053672 @default.
• W2994489315 hasAuthorship W2994489315A5045560136 @default.
• W2994489315 hasAuthorship W2994489315A5049667988 @default.
• W2994489315 hasAuthorship W2994489315A5053086036 @default.
• W2994489315 hasAuthorship W2994489315A5057776837 @default.
• W2994489315 hasAuthorship W2994489315A5061906116 @default.
• W2994489315 hasAuthorship W2994489315A5063736852 @default.
• W2994489315 hasConcept C126322002 @default.
• W2994489315 hasConcept C134018914 @default.
• W2994489315 hasConcept C185592680 @default.
• W2994489315 hasConcept C2776151105 @default.
• W2994489315 hasConcept C2776379505 @default.
• W2994489315 hasConcept C2778525890 @default.
• W2994489315 hasConcept C2778589496 @default.
• W2994489315 hasConcept C2779679481 @default.
• W2994489315 hasConcept C2780675426 @default.
• W2994489315 hasConcept C71924100 @default.
• W2994489315 hasConcept C98274493 @default.
• W2994489315 hasConceptScore W2994489315C126322002 @default.
• W2994489315 hasConceptScore W2994489315C134018914 @default.
• W2994489315 hasConceptScore W2994489315C185592680 @default.
• W2994489315 hasConceptScore W2994489315C2776151105 @default.
• W2994489315 hasConceptScore W2994489315C2776379505 @default.
• W2994489315 hasConceptScore W2994489315C2778525890 @default.
• W2994489315 hasConceptScore W2994489315C2778589496 @default.
• W2994489315 hasConceptScore W2994489315C2779679481 @default.
• W2994489315 hasConceptScore W2994489315C2780675426 @default.
• W2994489315 hasConceptScore W2994489315C71924100 @default.
• W2994489315 hasConceptScore W2994489315C98274493 @default.
• W2994489315 hasIssue "2" @default.
• W2994489315 hasLocation W29944893151 @default.
• W2994489315 hasOpenAccess W2994489315 @default.
• W2994489315 hasPrimaryLocation W29944893151 @default.
• W2994489315 hasRelatedWork W110910239 @default.
• W2994489315 hasRelatedWork W1781372697 @default.
• W2994489315 hasRelatedWork W1963837818 @default.
• W2994489315 hasRelatedWork W1968268702 @default.
• W2994489315 hasRelatedWork W2022600413 @default.
• W2994489315 hasRelatedWork W2040844633 @default.
• W2994489315 hasRelatedWork W2098249099 @default.
• W2994489315 hasRelatedWork W2157645473 @default.
• W2994489315 hasRelatedWork W2312942238 @default.
• W2994489315 hasRelatedWork W2899084033 @default.
• W2994489315 hasVolume "69" @default.
• W2994489315 isParatext "false" @default.
• W2994489315 isRetracted "false" @default.
• W2994489315 magId "2994489315" @default.
• W2994489315 workType "article" @default.